-
Kidney Cancer Drugs Market Size, Share, Revenue, Trends And Drivers For 2024-2033
26 Mar 2024 15:00 GMT
… ), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib … treatments are known as systemic therapy. Several different types of medications … com/report/drugs-for-immunotherapy-global-market-report …
-
2023 First Generic Drug Approvals
08 Mar 2024 22:36 GMT
… Pharmaceuticals, Inc.
Votrient (Pazopanib) Tablets
10/19/2023
For the treatment … ) Pharmacy Bulk Package
B. Braun Medical, Inc.
Calcium Gluconate in Sodium … that are refractory to other drugs
18
213267
Thalidomide Capsules USP …
-
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
07 Mar 2024 15:27 GMT
… March 5, 2024
TRACON Pharmaceuticals, Inc. beats earnings expectations … rate of Votrient, the only FDA-approved treatment for patients … last year to a biotech company that recognized the … evaluate drug candidates where TRACON performs clinical trials at …
-
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
06 Dec 2023 22:37 GMT
… U.S. Food and Drug Administration
Afami-cel data … to thank the trial participants and clinical trial investigators, the … FDA approved therapy for treatment in this setting was for Votrient … development activities and clinical trials and our ability to …
-
Trial Results Confirm Effectiveness of Atezolizumab Against a Rare Sarcoma
20 Oct 2023 17:09 GMT
… also provides hope that trials in rare cancers are … have been exploring newer treatments, including targeted therapies, but … One targeted therapy, pazopanib (Votrient), has been approved for … atezolizumab, provided the drug for the trial under a special …
-
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
28 Sep 2023 20:11 GMT
… of Kisqali®, Afinitor® and Votrient®, as well as other novel … , Dr. Voi was Chief Medical and Development Officer at Curis … of early-stage drug development and the treatment of solid tumors … or observations in earlier clinical trials will be representative of …
-
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 2023 20:02 GMT
… sole approved treatment for these patients is Votrient, which achieved … and 3D Medicines. TRACON has received orphan drug designation from … and scope of clinical trials and availability of … required by law.
TRACON Pharmaceuticals, Inc.
Unaudited Condensed …
-
October – December 2013 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
11 Jun 2023 17:00 GMT
… patients taking the drug should stop taking the medication. Patients who … inhibiting properties:
Lapatinib (Tykerb), Pazopanib (Votrient), Sorafenib (Nexavar), Sunitinib (Sutent)
… Mallinckrodt Pharmaceuticals (now held by SpecGx LLC) (Docket No. FDA–2016 …
-
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial
20 Jun 2023 12:00 GMT
… sole approved treatment for these patients is Votrient, which … 3D Medicines. TRACON has received orphan drug designation … ) The ENVASARC pivotal trial is a multicenter, … pharmaceutical product candidates; risks relating to cost variability of clinical trials …
-
July – September 2015 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
11 Jun 2023 17:03 GMT
… glyburide) tablet
Cardiovascular mortality
FDA decided that no action … Seizures
The “Ask a doctor before use if you … to include urosepsis.
Drugs@FDA for Labeling
Tecfidera ( … pneumonitis.
Votrient Labeling
Zonegran (zonisamide) capsule
Drug Reaction with …